Effectiveness of 225Ac-labeled anti-EGFR radio immunoconjugate in EGFR positive KRAS and BRAF mutant colorectal cancer models

被引：0
|
作者：
Tikum, Anjong [1 ]
Babeker, Hanan [2 ]
Ketchemen, Jessica Pougoue [2 ]
Fonge, Humphrey [2 ]
Njotu, Fabrice Ngoh [2 ]
Nambisan, Anand [2 ]
Doroudi, Alireza [2 ]
机构：
[1] Univ Saskatchewan Bookstore, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P222
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
    Morelli, M. Pia
    Overman, Michael J.
    Dasari, Arvind
    Kazmi, Syed Mohammad Ali
    Sanchez, Eduardo Vilar
    Eng, Cathy
    Kee, Bryan K.
    Deaton, Laurel
    Garrett, Chris R.
    Diehl, Frank
    Angenendt, Philipp
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
  • [23] KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
    Timar, J.
    Hegedus, B.
    Raso, E.
    CURRENT CANCER DRUG TARGETS, 2010, 10 (08) : 813 - 823
  • [24] The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer
    Xia, X.
    Du, W.
    Zhu, Y.
    Bai, Y.
    Liu, M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 218 - 218
  • [25] Acetylation is increased in KRAS mutated colorectal cancer cells that are resistant to anti-EGFR therapies
    Roda, D.
    Zaragoza, R.
    Fernandez, E.
    Torres, L.
    Garcia-Trevijano, E. R.
    Cervantes, A.
    FEBS JOURNAL, 2012, 279 : 311 - 312
  • [26] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
  • [27] Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
    Perkins, Geraldine
    Lievre, Astrid
    Ramacci, Carole
    Meatchi, Tchao
    de Reynies, Aurelien
    Emile, Jean-Francois
    Boige, Valerie
    Tomasic, Gorana
    Bachet, Jean-Baptiste
    Bibeau, Frederic
    Bouche, Olivier
    Penault-Llorca, Frederique
    Merlin, Jean-Louis
    Laurent-Puig, Pierre
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (06) : 1321 - 1331
  • [28] Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo, Sergio
    Bronte, Giuseppe
    Fanale, Daniele
    Corsini, Lidia
    Silvestris, Nicola
    Santini, Daniele
    Gulotta, Gaspare
    Bazan, Viviana
    Gebbia, Nicola
    Fulfaro, Fabio
    Russo, Antonio
    CANCER TREATMENT REVIEWS, 2010, 36 : S56 - S61
  • [29] 225Ac-labeled anti-EphA2/EGFR bispecific radioimmunoconjugate prolongs survival of mice bearing triple negative breast cancer xenograft
    Khan, B.
    Solomon, R.
    Alizadeh, E.
    Thiele, N.
    Causey, P.
    Perron, R.
    Gendron, D.
    Wilson, J.
    Behzad, T.
    Vizeacoumar, F.
    Freywald, A.
    Fonge, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S409 - S410
  • [30] Screening for KRAS and BRAF mutations may reduce the costs associated with anti-EGFR therapy for colon cancer
    不详
    COLORECTAL CANCER, 2013, 2 (01) : 19 - 20
12345